We are thrilled to announce significant advancements at Astherna! Our team is experiencing significant growth. Starting December 1st, Melita Kaltak has become a valuable addition to our Research Team, where she will be focused on advancing the development of antisense oligonucleotides tailored for the treatment of retinal diseases.
Furthermore, we are pleased to announce the inclusion of Cathaline den Besten and Bianca Matthee in our Drug Development Team! Both bring extensive expertise in the development of antisense oligonucleotides for inherited retinal diseases.
With the support of these accomplished professionals, Astherna continues to fortify its team of distinguished experts. We are confident in our ability to persistently advance the development of RNA-based treatments, particularly for Stargardt and Usher syndrome patients, who currently lack accessible treatment options.